Component
Lactulose
Disaccharide used at a 4 g/day food-level dose in the cited exploratory skin-emission study; clinical-dose effects are not inferred.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What it acts on
The human lactulose time course showed no apparent increasing trend in gamma-nonalactone skin emission.
Experimental context and source evidence
- dose
- Lactulose 4 g/day; no administered gamma-nonalactone
- duration
- 2 weeks; baseline days 1-2 and follow-up days 6, 10 and 17
- evidence_access
- Primary full-text methods/results inspected; PubMed metadata where indexed.
- evidence_scope
- literature_reviewed; model-specific source-derived curation
- experimental_model
- Exploratory healthy-human lactulose study; six participants in time-course cohort, ten in expanded correlation analysis
- limitations
- Small uncontrolled study; no apparent C9 trend is not proof of universal absence of effect. Significant C10/C11 increases must not be transferred to C9 gamma-nonalactone; SCFA mediation remains proposed.
- nutrient_topic
- Gamma-nonalactone flavor-compound chapter; nutrient and drug interactions retain their experimental settings. · Gamma-nonalactone
- organism
- Exploratory healthy-human lactulose study; six participants in time-course cohort, ten in expanded correlation analysis
- plain_language
- The human lactulose time course showed no apparent increasing trend in gamma-nonalactone skin emission.
- primary_references
- Influence of Ingestion of Lactulose on gamma-Lactones Emanating from Human Skin Surface (2023). https://www.mdpi.com/2076-3417/13/6/3930 DOI: 10.3390/app13063930
- route
- Oral lactulose; passive skin-gas sampling
- tissue
- Forearm volatile emission measured by passive sampling and GC-MS
Gamma-nonalactone: mechanisms, molecular forms and cross-actor connections (2026-09-20) · lines 257–266
Original AI-assisted curation of eight primary studies. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Exploratory healthy-human lactulose study; six participants in time-course cohort, ten in expanded correlation analysis · source_derived_draft · unverified_draft
## gamma-nonalactone-lactulose-skin-null The human lactulose time course showed no apparent increasing trend in gamma-nonalactone skin emission. Model/species: Exploratory healthy-human lactulose study; six participants in time-course cohort, ten in expanded correlation analysis Tissue: Forearm volatile emission measured by passive sampling and GC-MS Exposure: Lactulose 4 g/day; no administered gamma-nonalactone Route: Oral lactulose; passive skin-gas sampling Duration: 2 weeks; baseline days 1-2 and follow-up days 6, 10 and 17 Limits: Small uncontrolled study; no apparent C9 trend is not proof of universal absence of effect. Significant C10/C11 increases must not be transferred to C9 gamma-nonalactone; SCFA mediation remains proposed. Primary reference: Influence of Ingestion of Lactulose on gamma-Lactones Emanating from Human Skin Surface (2023). https://www.mdpi.com/2076-3417/13/6/3930 DOI: 10.3390/app13063930 Access: Primary full-text methods/results inspected; PubMed metadata where indexed.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.